Eleanor N. Dana Cancer Center

/centers/cancer/
/centers/cancer/

Services

/  

Contact Us

Clinical trials at the Eleanor N. Dana Cancer Center

Consult your medical team to find out whether you are a candidate for one of our clinical trials. Since we are constantly expanding the list of clinical trials we offer, if you don't see your cancer indication listed below please contact the Eleanor N. Dana Cancer Center at 419.383.6644. You can learn more about clinical trials here.


Advanced Cancers

A Phase 1/2 Study of Tremelimumab/Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist (PolyICLC) in Advanced Cancer

Mechanism:  Combination CTLA-4 of PD-L1 inhibition CTLA-4 against to enhance antitumor immune response

+ More Info

All Cancer Indications

Molecular Target Registry

+ More Info

Bladder Cancer

Phase 2 Trial of CV301, PD-1-PDL-1 blockade in advanced Bladder Cancer

Mechanism:  A targeted immune therapeutic approach with CV301 a tumor targeting vaccinia virus carrying tumor antigens MUC1, CEA and immune stimulating signals B7.1, LFA3 and ICAM1 to induce activation of anti-tumor immune effector T-cells which will have greater tumor penetration when combined with check point inhibitor therapy.

+ More Info

A Phase 1/2 Study of Tremelimumab/Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist (PolyICLC) in Advanced Cancer

Mechanism:  Combination CTLA-4 of PD-L1 inhibition CTLA-4 against to enhance antitumor immune response

+ More Info

BC-819 Bladder Cancer Unresponsive to BCG

Mechanism:  BC-819 is a plasmid DNA encoding diphtheria toxin (DT) under H19, a cancer gene promoter control. H19 promoter expression of DT is limited to cancer thus is selective in inducing cancer necrosis.

+ More Info

Blood Cancer

MDS/AML Registry

+ More Info

Brain Cancer

Phase 2 Recurrent GBM Cancer Stem Cell ChemoID

Mechanism:  Stem cell assay utilized to define surgically removed live tumor response to stem cell targeting therapy selection and treatments.

+ More Info

Randomized trial DSP-7888 with Bevacizumab vs. Bevacizumab Alone

Mechanism:  Immune modulatory vaccine.

+ More Info


Breast Cancer

Phase 2 Talazoparib ADP ribose polymerase 1 with early TNBC

Mechanism:  PARP inhibitor with optimal activity in DNA repair deficient tumor response.

+ More Info

Phase I study of KN026 in HER2 cancer

Mechanism:  Anti-HER2 bispecific antibody to non overlapping HER2 epitopes

+ More Info

A Phase 1/2 Study of Tremelimumab/Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist (PolyICLC) in Advanced Cancer

Mechanism:  Combination CTLA-4 of PD-L1 inhibition CTLA-4 against to enhance antitumor immune response

+ More Info


Colorectal Cancer

Phase 1 Study of NBF-006 in Advanced Solid Tumor

Mechanism:  siRNA targeting Glutathione S-transferase P (GSTP) which modulates ras signaling.  Control of GSTP will inhibit ras signaling as related to cancer growth.  Most relevant to ras mutant positive tumors.

+ More Info


GIST

Phase 3 Clinical Trial in advanced GIST patients with DCC-2618 KIT/PDGFR inhibitor

Mechanism:  Selective KIT/PDGRF kinase inhibitor.

+ More Info


Head and Neck Cancer

Phase 2 Ad-p53 + Nivo in HNSCC

Mechanism:  Ad-p53 is an expressive DNA plasmid which prevents genome mutation expression and plays a role in signaling anti-tumor immunity. It suppresses specifically TGFβ and β-catenin which are tumor immune suppressors and upregulates tumor cell antigen receptors which increase NK and macrophage antitumor activity.

+ More Info

A Phase 1/2 Study of Tremelimumab/Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist (PolyICLC) in Advanced Cancer

Mechanism:  Combination CTLA-4 of PD-L1 inhibition CTLA-4 against to enhance antitumor immune response

+ More Info

Hepatocellular Cancer

Phase I Trial of INCB062079 in Advanced Hepatocellular Carcinoma and Other Malignancies

Mechanism:  FGFR4 inhibitor

+ More Info


Phase III study of Cabozantinib/Atezolizumab vs. Sorafenib in front line advanced hepatocellular cancer

Mechanism:  Cabozantinib is a small molecular tyrosine kinase inhibitor of VEGFR, MET, AXL and RET

+ More Info


Lung Cancer

Lung Hypo-IMRT with Carboplatin and Paclitaxel for Patients with Stage IIIA or IIIB Non-Small Cell Lung Cancer

+ More Info

Phase 1 Study of NBF-006 in Advanced Solid Tumor

Mechanism:  siRNA targeting Glutathione S-transferase P (GSTP) which modulates ras signaling.  Control of GSTP will inhibit ras signaling as related to cancer growth.  Most relevant to ras mutant positive tumors.

+ More Info


Melanoma

A Phase 1/2 Study of Tremelimumab/Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist (PolyICLC) in Advanced Cancer

Mechanism:  Combination CTLA-4 of PD-L1 inhibition CTLA-4 against to enhance antitumor immune response

+ More Info

Mesothelioma

Phase 3 Mesothelioma/Ad IFN/Celecoxib/GEM

Mechanism:  Replicating deficient adenovirus expressive of interferon Alpha-2 beta which enhances immune function at pleural effusion tumor site when directly injected.

+ More Info


Multiple Myeloma

Randomized Trial Ixazomib/Dexamethasone vs. Pomalidomide/Dexamethasone in Refractory Multiple Myeloma

Mechanism:  Ixazomib is a proteosome subunit beta type 5 inhibitor. Pomalidomide is an anti-angiogenic immune modulator derivative of thalidomide. Both have demonstrated activity towards cellular compromise delay in MM.

+ More Info


Pancreatic Cancer

Phase 1 Study of NBF-006 in Advanced Solid Tumor

Mechanism:  siRNA targeting Glutathione S-transferase P (GSTP) which modulates ras signaling.  Control of GSTP will inhibit ras signaling as related to cancer growth.  Most relevant to ras mutant positive tumors.

+ More Info

Phase 1B of C3 in Adv Pancreatic and Solid Tumor Cancer

Mechanism:  Combination Metformin, Digoxin, Simvastatin (C3) knocks down BIRC5, a dominant cancer stimulatory protein.

+ More Info


Peritoneal

Phase 1/2 ONCOS-102 + Durva in Adv Peritoneal Malignancies

Mechanism:  Gene modified tumor replication capable adenovirus (Oncos-102) expressive of GMCSF which enhances tumor antigen expression and improves effector T cell function in combination with Durvalumab (checkpoint inhibitor) to enhance immune antitumor response.

+ More Info


Renal

A Phase 1/2 Study of Tremelimumab/Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist (PolyICLC) in Advanced Cancer

Mechanism:  Combination CTLA-4 of PD-L1 inhibition CTLA-4 against to enhance antitumor immune response

+ More Info

Solid Tumor

Phase 1/2 PK / PD Study of APS001F in Metastatic Solid Tumors

Mechanism:  APS001F will deliver cytosine deaminase (CD) expressive DNA selectively to tumor microenvironment. Once these oral 5-Flucytosine will be given and will be converted to 5FU by expressed CD activity 20 fold higher (limited to tumor site) than can be achieved by IV 5FU.

+ More Info

Phase I Study ASP9801 in Solid Tumors

Mechanism:  Cancer oncolysis

+ More Info

A Phase 1/2 Study of Tremelimumab/Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist (PolyICLC) in Advanced Cancer

Mechanism:  Combination CTLA-4 of PD-L1 inhibition CTLA-4 against to enhance antitumor immune response

+ More Info

For more information about the clinical trials that are offered at the Eleanor N. Dana Cancer Center please contact Stephanie Smiddy at 419.383.6962
/
Last Updated: 9/10/19